Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters








Database
Language
Publication year range
1.
Cancer Immunol Res ; 3(10): 1109-14, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26438443

ABSTRACT

The world of lymphocytes has recently expanded. A group of cells, innate lymphoid cells (ILC), has been defined. It includes lymphoid cells that have been known for decades, such as natural killer (NK) cells and lymphoid tissue-inducer (LTi) cells. NK cells recognize a vast array of tumor cells, which they help to eliminate through cytotoxicity and the production of cytokines, such as IFNγ. Advances in our understanding of NK-cell biology have led to a growing interest in the clinical manipulation of these cells in cancer. The other ILCs are found mostly in the mucosae and mucosal-associated lymphoid tissues, where they rapidly initiate immune responses to pathogens without the need for specific sensitization. Here, we outline the basic features of ILCs and review the role of ILCs other than NK cells in cancer. Much of the role of these ILCs in cancer remains unknown, but several findings should lead to further efforts to dissect the contribution of different ILC subsets to the promotion, maintenance, or elimination of tumors at various anatomic sites. This will require the development of standardized reagents and protocols for monitoring the presence and function of ILCs in human blood and tissue samples.


Subject(s)
Immunity, Innate , Lymphocyte Subsets/immunology , Neoplasms/immunology , Animals , Humans , Immunophenotyping , Killer Cells, Natural/immunology , Killer Cells, Natural/metabolism , Lymphocyte Subsets/metabolism , Neoplasms/metabolism , Neoplasms/pathology , Neoplasms/therapy , Phenotype
2.
Cytotherapy ; 11(6): 804-6, 806.e1, 2009.
Article in English | MEDLINE | ID: mdl-19878066

ABSTRACT

Guidelines for flow cytometric enumeration of CD34(+) hematopoietic stem cells (HSC) recommend the use of a single-platform assay. The SCE kit has recently been commercialized by BD Biosciences. Results obtained with this newly available kit were compared with CD34(+) cell enumerations obtained in parallel with already commercialized diagnostic kits; fresh peripheral blood, apheresis, cord blood (CB) and bone marrow (BM) samples, as well as thawed apheresis and CB samples, were assayed. The SCE kit produced data for CD34(+) enumeration that correlate well with data produced with the older assays (r(2) > or = 0.9). Practical advantages were the ability to enumerate viable CD34 cells in all kinds of HSC products, the absence of bead pipetting (which decreases results precision) and a gating strategy complying with international recommendations. A major disadvantage was the absence of specific software for data analyses and presentation of results.


Subject(s)
Cell Count/methods , Flow Cytometry/methods , Hematopoietic Stem Cells/cytology , Antigens, CD34/metabolism , Humans , Reagent Kits, Diagnostic
SELECTION OF CITATIONS
SEARCH DETAIL